I'll say; I was expecting +/- 55c on the back of the US DoD writing a blank cheque to get this drug over the finish line.
Then +/- 80c upon further positive results of PCSK9 inhibitor proof of concept study in June/July.
When you consider the sheer lack of shares available to the public if even just one of these drugs reaches the market... It's retirement stock on the dividends alone.
Ann: NYR Secures Collaboration with Walter Reed and UNSW, page-37
-
- There are more pages in this discussion • 29 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
